TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23823808
Drug: Post-ERCP somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-ERCP somatostatin (0.5 mg/h for 24 hours, starting 1 hour after ERCP)
Study: 14971716
Drug: Mao-to (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mao-to (herbal medicine)
Study: 8428715
Drug: Selective parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective parenteral and enteral antimicrobial regimen (group 2)
Study: 8428715
Drug: Selective parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective parenteral and enteral antimicrobial regimen (group 3)
Study: 8428715
Drug: Selective parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective parenteral and enteral antimicrobial regimen (groups 2 and 3)
Study: 8428715
Drug: Early antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early antimicrobial therapy (groups 1, 2, and 3)
Study: 3314469
Drug: Insulin adjustment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin adjustment based on carbohydrate amount
Study: 29340888
Drug: Wet Cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet Cupping Therapy (WCT) for 10 min
Study: 21796252
Drug: Olmesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan plus Azelnidipine (16 mg daily)
Study: 21796252
Drug: Olmesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan plus Amlodipine (5 mg daily)
Study: 10951632
Drug: Cisapride (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.2 mg/kg/dose every 8 hours for 14 days)
Study: 9028717
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (35 mg of 20:5 omega 3 + 22:6 omega 3.kg body weight‐1.day‐1)
Study: 9028717
Drug: Linseed oil
Normalized name: linseed oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linseed oil supplement (35 mg of 18:3 omega 3.kg body weight‐1.day‐1)
Study: 9028717
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil supplement (placebo, 35 mg of 18:1.kg body weight‐1.day‐1)
Study: 8281591
Drug: Midazolam (0.2‐0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2‐0.3 mg.kg‐1)
Study: 8281591
Drug: Diazepam (0.3‐0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.3‐0.4 mg.kg‐1)
Study: 8281591
Drug: Flunitrazepam (0.03‐0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.03‐0.04 mg.kg‐1)
Study: 3046411
Drug: Intravenous glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose-insulin-potassium infusion
Study: 3046411
Drug: Conventional subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subcutaneous insulin administration
Study: 28478972
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg once weekly plus topical corticosteroids
Study: 28478972
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks plus topical corticosteroids
Study: 6120142
Drug: Acebutolol (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (dosage not specified)
Study: 26378561
Drug: Low-dose simvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose simvastatin and health education
Study: 19685108
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine 5'-triphosphate (ATP) infusion at a rate of 160 microg.kg(‐1).min(‐1) throughout surgery
Study: 19685108
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine 5'-triphosphate (ATP) infusion
Study: 17334459
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) (Group TIVA)
Study: 9626919
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol ophthalmic solution
Study: 9626919
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol ophthalmic solution with oral nicardipine (40 mg)
Study: 9626919
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol ophthalmic solution with oral diltiazem (60 mg)
Study: 9626919
Drug: Oral nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicardipine (40 mg)
Study: 9626919
Drug: Oral diltiazem
Normalized name: diltiazem Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diltiazem (60 mg)
Study: 2894747
Drug: ICI 141.292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141.292 (100 mg once daily)
Study: 2894747
Drug: ICI 141.292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141.292 (200 mg once daily)
Study: 2894747
Drug: ICI 141.292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141.292 (300 mg once daily)
Study: 28109665
Drug: Low-dose olanzapine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose olanzapine (5mg/day) plus low-dose trifluoperazine (5mg/day)
Study: 28109665
Drug: Full-dose olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose olanzapine (10mg/day)
Study: 8987323
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of oral elemental calcium per day (n = 103)
Study: 1639618
Drug: Levodopa, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa, administered daily for 1 week
Study: 1639618
Drug: Previous study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous study with a single dose of levodopa
Study: 23937297
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group received 2 individualized feedback sessions regarding safety and productivity-related issues in daily verbal exchanges.
Study: 18686768
Drug: Root debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root debridement with Gracey curettes and root brushing with 40% tetracycline gel
Study: 18686768
Drug: Root debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root debridement with Gracey curettes and root brushing with saline solution
Study: 7836084
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy and CMF chemotherapy simultaneously
Study: 7836084
Drug: Simultaneous radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous radiation therapy and chemotherapy
Study: 2403061
Drug: Intravenous maltose
Normalized name: Maltose
DrugBank: Maltose (DB03323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous maltose infusion
Study: 2403061
Drug: Simultaneous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous glucose infusion
Study: 24072234
Drug: B-ultrasound-guided IHP
Normalized name: MAGNI-GUIDE (B-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-ultrasound-guided IHP with 45 °C physiological saline solution and cisplatin (PSS-C)
Study: 16594930
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (menatetrenone) 45 mg and calcium carbonate 1500 mg per day
Study: 16594930
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and calcium carbonate 1500 mg per day
Study: 12690583
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy (3 times weekly for 6 weeks)
Study: 12690583
Drug: Progressive‐resistive robotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive‐resistive robotic therapy
Study: 12690583
Drug: Sensorimotor robotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensorimotor robotic therapy
Study: 9661615
Drug: Deslorelin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deslorelin at a dose of 1 microgram/kg.day
Study: 9661615
Drug: Deslorelin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deslorelin at a dose of 2 micrograms/kg.day
Study: 9661615
Drug: Deslorelin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deslorelin at a dose of 4 micrograms/kg.day
Study: 8001357
Drug: Vaccine for
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine for the prevention of haemophilus influenzae type b
Study: 8001357
Drug: Prior probability
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior probability distribution of vaccine efficacy
Study: 8001357
Drug: Probability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probability of regulatory approval for widespread use of the vaccine
Study: 3390997
Drug: gallopamil 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil 37.5 mg t.i.d.
Study: 2647495
Drug: gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil 50 mg t.i.d.
Study: 8256213
Drug: Levothyroxine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine at substitutive dosage (100 micrograms)
Study: 8256213
Drug: Levothyroxine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine at suppressive dosage (2.2 to 3 micrograms/kg/day)
Study: 356724
Drug: Cefamandole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (1 g every 6 h)
Study: 31339594
Drug: Sarpogrelate with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate with high-dose statin (Group A, n = 25)
Study: 31339594
Drug: Sarpogrelate with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate with low-dose or no statin (Group B, n = 25)
Study: 31339594
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with high-dose statin (Group C, n = 25)
Study: 31339594
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with low-dose or no statin (Group D, n = 25)
Study: 31339594
Drug: High-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statin (compared to low-dose or no statin)
Study: 17289576
Drug: Bromocriptine, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine, an inhibitor of prolactin secretion
Study: 12195694
Drug: B-vitamin supplements
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplements (5 mg folic acid, 0.4 mg hydroxycobalamin, and 50 mg pyridoxine) daily for 8 weeks
Study: 12195694
Drug: B-vitamin supplements
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplements
Study: 8017326
Drug: Flaxseed powder
Normalized name: Flaxseed Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed powder (10 g/d)
Study: 2808261
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) at a mean maximal daily oral dose of 4.6 +/- 0.2 mg/kg for 6 weeks.
Study: 2808261
Drug: DMI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMI treatment above 3.5 mg/kg.
Study: 1096927
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g ascorbic acid daily
Study: 23498759
Drug: Infra-low-frequency transcranial
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infra-low-frequency transcranial magnetic stimulation (in addition to conventional comprehensive rehabilitation therapy)
Study: 23498759
Drug: Conventional comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional comprehensive rehabilitation therapy
Study: 21332798
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination plus pre-biotics
Study: 18250112
Drug: Benzbromarone 200
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone 200 mg/day
Study: 18250112
Drug: Probenecid 2
Normalized name: probenecid 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid 2 g/day
Study: 15164330
Drug: Acipimox (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (500 mg orally at 2 am and again at 6 am)
Study: 10676671
Drug: Diuretic agents
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic agents
Study: 10676671
Drug: Sublingual NTG
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual NTG
Study: 10676671
Drug: NG‐monomethyl‐L‐arginine (NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (NO synthase inhibitor)
Study: 1488570
Drug: Inhaled gallopamil
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled gallopamil (10 mg)
Study: 23956241
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg/d)
Study: 28835359
Drug: Maternal antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibodies against malaria vaccine candidate antigens
Study: 28835359
Drug: Vaccination of
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination of mothers with malaria vaccine during pregnancy
Study: 23902797
Drug: Self-directed intervention
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed intervention (adjunct motivational and autonomy-enhancing approach)
Study: 23902797
Drug: Prescribed intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed intervention (standard prescription of uniform behavioral skills use and interventionist goal assignment)
Study: 12840090
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg per kilogram per day)
Study: 12840090
Drug: Cyclophosphamide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (1.5 mg per kilogram of body weight per day)
Study: 10373765
Drug: Psychodynamically oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamically oriented treatment, median duration of therapy approximately 11 weeks.
Study: 10373765
Drug: Psychodynamically oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamically oriented treatment
Study: 8712092
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg
Study: 8712092
Drug: Bicalutamide 80
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 80 mg
Study: 8712092
Drug: Bicalutamide 100
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 100 mg
Study: 7332916
Drug: Flubendazole, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flubendazole, 100 mg twice a day for three days
Study: 7332916
Drug: Mebendazole, 100
Normalized name: Mebendazole, 100 mg oral tablet, chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole, 100 mg twice a day for three days
Study: 28867499
Drug: Bictegravir 50
Normalized name: bictegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir 50 mg, Emtricitabine 200 mg, Tenofovir Alafenamide 25 mg
Study: 28867499
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg, Emtricitabine 200 mg, Tenofovir Alafenamide 25 mg
Study: 23490572
Drug: Web-delivered brief
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Web-delivered brief alcohol intervention (BAI) plus treatment as usual (TAU)
Study: 19833610
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of autologous mononuclear bone marrow cells (mBMCs), n=50
Study: 12620292
Drug: IFN alpha‐2c
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2c (3.5 MU/d) plus araC (10 mg/m(2) d1‐10)
Study: 12620292
Drug: IFN alpha‐2c
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2c (3.5 MU/d) plus hydroxyurea (HU: 25 mg/kg per day)
Study: 11095473
Drug: Continuous GH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous GH infusion (2 IU/m2-24 h)
Study: 11095473
Drug: Pulsatile GH
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile GH administration (eight bolus injections)
Study: 11095473
Drug: Both continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both continuous and pulsatile GH administration
Study: 3510458
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg and 0.6 mg
Study: 3510458
Drug: Pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 30 mg and 60 mg
Study: 25753488
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg daily
Study: 20516676
Drug: Naftopidil 75
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 75 mg once daily (OD) in the evening (group O; n = 41)
Study: 20516676
Drug: Naftopidil 25
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 25 mg thrice daily (TID) in the morning, afternoon, and evening (group T; n = 39)
Study: 18230388
Drug: He-Ne laser
Normalized name: Ne
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: He-Ne laser (lambda = 632.8nm, output = 10 mW, energy density = 1.8 J/cm(2)) for 8 days, followed by laser probe treatment at 6 anatomic sites for 5 minutes each.
Study: 12030875
Drug: Avène spring
Normalized name: avens extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avène spring water spray in conjunction with petrolatum ointment
Study: 12030875
Drug: Petrolatum ointment
Normalized name: GERI PROTECT Petrolatum Ointment
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum ointment alone
Study: 10334658
Drug: 0.83 g
Normalized name: SODIUM MONOFLUOROPHOSPHATE 0.83 g in 100 g ORAL PASTE, DENTIFRICE [Plus White]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.83 g plant sterols
Study: 10334658
Drug: 1.61 g
Normalized name: Dimethicone 1.61 g in 50 mL TOPICAL GEL [SKINMD LABORATORIES REVIGE L]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.61 g plant sterols
Study: 10334658
Drug: 3.24 g
Normalized name: urologic solution-G 3.24 gram-380 mg-430 mg/100 mL IRRIGATION SOLUTION, IRRIGATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.24 g plant sterols
Study: 3971682
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous (i.v.) morphine sulfate for 24 hours
Study: 3971682
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) morphine sulfate for 24 hours
Study: 3971682
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous (i.v.) morphine sulfate
Study: 3971682
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) morphine sulfate
Study: 22522414
Drug: Mandibular conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular conventional denture or implant overdenture
Study: 20490465
Drug: Naltrexone (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (0, 12, 25, 50, or 100 mg) with active marijuana (3.27% THC)
Study: 20490465
Drug: Naltrexone (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (0, 12, 25, 50, or 100 mg) with inactive marijuana (0% THC)
Study: 18581595
Drug: Supervised moderate‐intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised moderate‐intensity exercise therapy for 50 min 3 times per week for 5 weeks
Study: 11815427
Drug: Blockade of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockade of ET(A) and ET(B) receptors using BQ-123 (100 nmol/min) and BQ-788 (50 nmol/min)
Study: 11815427
Drug: Blockade of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockade of ET(A/B) receptors
Study: 12625832
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) administration
Study: 11815427
Drug: ET-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ET-1 receptor antagonism
Study: 1523288
Drug: ritanserin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritanserin (5 mg orally)
Study: 6337285
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g/day of elemental calcium)
Study: 19614687
Drug: Carbachol (3 µg/kg)
Normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbachol (3 µg/kg)
Study: 17039266
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cyclophosphamide, methotrexate, fluoracil)
Study: 17039266
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (low-risk patients not on chemotherapy)
Study: 16313543
Drug: Doubling daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling daily inhaled corticosteroid (ICS) dose (fluticasone)
Study: 16313543
Drug: Maintaining usual
Normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintaining usual ICS dose
Study: 16313543
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (OS) (dexamethasone)